113: After slow IPO, Gland Pharma finds more takers in secondary markets

Whoever stuck their neck out in the Gland Pharma IPO is already sitting on decent gains. For an issue that offered full allotment for every application in the non-institutional category, it’s been among the best-performing IPOs for investors. Tune in here for more details.

132 Episodes

22 Dec 2024

62: RBI stress tests show a grim asset quality outlook for banks

6 MINS

22 Dec 2024

61: ICICI Pru life Fares Better In Q1 Whereas SBI Life & HDFC Life Show Lockdown Impact

6 MINS

22 Dec 2024

60: With no bailout, how are India's domestic airlines surviving?

7 MINS

22 Dec 2024

59: Yes Bank gets a second chance at survival

6 MINS

22 Dec 2024

58: Key takeaways from RIL's AGM and implications for the stock

6 MINS

22 Dec 2024

57: DMart Q1FY21 profit almost vanishes; stock now trades at 140 times earnings

7 MINS

22 Dec 2024

56: Why TCS investors should not mimic those of Accenture?

6 MINS

22 Dec 2024

55: Titan’s recovery in June comforts but stock’s valuations are shimmering already

6 MINS

22 Dec 2024

54: Even as IndusInd, Federal Bank feel COVID blues in Q1FY21, HDFC Bank shows loan growth

6 MINS

22 Dec 2024

53: HDFC and group companies may eye acquisitions amid COVID-19

6 MINS

< 1 … 6 7 8 9 10 … 14 >